Lexicon rises on plan to resubmit marketing application for diabetes drug

Lexicon Pharmaceuticals

11/03/2024 12:45

** Shares of Lexicon Pharmaceuticals  LXRX.O  rise ~6% to
$2.29 premarket
    ** Co says it is preparing to resubmit its marketing
application for the drug sotagliflozin as an adjunct to insulin
therapy in patients with type 1 diabetes who have chronic kidney
disease
    ** Says the resubmission is planned for mid-2024
    ** Co also reports Q4 loss of 20 cents/shr vs analysts'
average loss estimate of 22 cents/shr - LSEG data
    ** Up to last close, stock down 4% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))